New generation of organic herb-based medical supplies is one of the top headlines in related industry news for some time. However, there are no answers regarding the exact moment when these products will become available on the shelves of pharmacies. Pharmaceutical corporations still have to solve the roughage problem. It’s even not about the quality but about a possibility of regular obtaining it in sufficient amounts. Leading German pharmaceutical companies can only use export raw materials, since the cultivation of medical cannabis is prohibited in Germany.

The recent permission to distribute medicinal cannabis roughage opens wide possibilities for Israeli manufacturers. Although the demand remains diverse, GROUP1607 concentrates on the production of high-quality products, which are going to win the market in the nearest 12-18 months, according to our experts’ forecasts.